ArticleThe British journal of ophthalmology2006
Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice.
Article in The British journal of ophthalmology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Involvement of the PD-1 pathway in the modulation of immune responses during allergic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Pathophysiological and molecular insights into allergic conjunctivitis: an expanding analysis of immunological endotypes.Frontiers in allergy · 2026Review
- Dose-response relationship and predictive value of soluble B7-DC in bronchoalveolar lavage fluid and risk of refractory Mycoplasma pneumoniae pneumonia in children.The Kaohsiung journal of medical sciences · 2025Article
- The predictive values of soluble B7-DC in children with refractory mycoplasma pneumoniae pneumonia.Translational pediatrics · 2023Article
- New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.International journal of molecular sciences · 2021Review
- The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.Pharmaceuticals (Basel, Switzerland) · 2021Review
- PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis.Frontiers in immunology · 2021Article
- B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Article
- Role of PD-L1 and PD-L2 in allergic diseases and asthma.Allergy · 2011Review
- Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.American journal of respiratory cell and molecular biology · 2010Article
- Aggravation of conjunctival early-phase reaction by Staphylococcus enterotoxin B via augmentation of IgE production.Japanese journal of ophthalmology · 2010Article
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.International immunology · 2010Article
- The role of costimulatory molecules in allergic disease and asthma.International archives of allergy and immunology · 2010Review
- Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.Rheumatology (Oxford, England) · 2008Article
- Article
- PD-1 and its ligands in tolerance and immunity.Annual review of immunology · 2008Review
- Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimInvolvement of programmed death-1 (PD-1) and its ligands has been demonstrated in experimental allergic airway disease. Here, the authors aimed to examine whether PD-1 and its ligands are involved in the development of experimental allergic conjunctivitis (EC) in mice.
methodsEC was induced in Balb/c mice by active immunisation with short ragweed pollen (RW) in alum. 10 days later (day 10), the mice were challenged with eye drops containing RW. 24 hours after the challenge, conjunctivas, spleens, and sera were harvested for histological analysis, cytokine assays, and measurement of RW specific Ig levels. The actively immunised mice were treated with anti-PD-1, anti-PD-L1, anti-PD-L2 antibodies (Abs), or normal rat immunoglobulin G (nrIgG) during either the induction (day 0, 2, 4, 6, and 8) or the effector (2 hours before RW challenge on day 10) phase.
resultsAb treatment during the induction phase did not affect eosinophil infiltration although immune responses were modulated. In contrast, treatment with anti-PD-L2 Ab, but not anti-PD-1 or anti-PD-L1 Ab, during the effector phase significantly increased eosinophil infiltration into the conjunctiva without affecting systemic immune responses.
conclusionsSimilar to allergic airway inflammation, PD-L2 is involved in the development of EC during the effector phase but not the induction phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.